TissuPath publications and collaborations

2016

• Incidental prostate cancer in transurethral resection of prostate specimens in men aged up to 65 years. Perera M, Lawrentschuk N, Perera N, Bolton D, Clouston D. Prostate Int. 2016;4 (1): 11-4.
• Management of Early Node-Positive Breast Cancer in Australia: A Multicentre Study. Gannan E, Khoo J, Nightingale S, Suhardja TS, Lippey J, Keane H, Tan KJ, Clouston D, Gorelik A, Mann GB; Breast J. 2016;22 (4): 413-9.
• High-Resolution Map of Somatic Peri-Prostatic Nerves. Reeves F, Battye S, Borin JF, Corcoran NM, Costello AJ. Urology. 2016;  [Epub ahead of print]
• The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer. Rebello RJ, Kusnadi E, Cameron DP, Pearson HB, Lesmana A, Devlin JR, Drygin D, Clark AK, Porter L,Pedersen J, Sandhu S, Risbridger GP, Pearson RB, Hannan RD, Furic L. Clin. Cancer Res. [Epub ahead of print]
• Routinely reported ‘equivocal’ lymphovascular invasion in prostatectomy specimens is associated with adverse outcomes. Galiabovitch E, Hovens CM, Peters JS, Costello AJ, Battye S, Norden S, Ryan A, Corcoran NM. BJU Int. 2016 [Epub ahead of print]
• Keystone Island Flap: Effects of Islanding on Vascularity. Lo CH, Nottle T, Mills J. Plast Reconstr Surg Glob Open. 2016;4 (2): e617.
• Validation of the novel ISUP-2014 5-tier Gleason grade grouping: Biochemical recurrence rates of 3+5 disease may be overestimated. van den Bergh RC, van der Kwast TH, de Jong J, Zargar H, Ryan AJ, Costello AJ, Murphy DG, van der Poel HG. BJU Int. 2016 [Epub ahead of print].
• Searching for candidate genes in familial BRCAX mutation carriers with prostate cancer. Hunter SM, Rowley SM, Clouston D; KCon Fab Investigators, Li J, Lupat R, Krishnananthan N, Risbridger G, Taylor R, Bolton D, Campbell IG, Thorne H. Urol. Oncol. 2016;34 (3): 120.e9-16.
• Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families. Li J, Meeks H, Feng BJ, Healey S, Thorne H, Makunin I, Ellis J; kConFab Investigators, Campbell I, Southey M,Mitchell G, Clouston D, Kirk J, Goldgar D, Chenevix-Trench G. J. Med. Genet. 2015;53 (1): 34-42.
• Subungual fibro-osseous pseudotumour of the toe. Meani RE, Bloom RJ, Battye S, Chamberlain AJ. Australas. J. Dermatol. 2016;57 (2): e57-60.

2015

• Magnetic resonance imaging for prostate cancer: Comparative studies including radical prostatectomy specimens and template transperineal biopsy. Toner L, Weerakoon M, Bolton DM, Ryan A, Katelaris N, Lawrentschuk N. Prostate Int. 2015;3 (4): 107-14.
• The polarity protein Scrib mediates epidermal development and exerts a tumor suppressive function during skin carcinogenesis. Pearson HB, McGlinn E, Phesse TJ, Schlüter H, Srikumar A, Gödde NJ, Woelwer CB, Ryan A, Phillips WA, Ernst M, Kaur P, Humbert P. Mol. Cancer. 2015;14 (1): 169.
• Establishment of primary patient-derived xenografts of palliative TURP specimens to study castrate-resistant prostate cancer. Lawrence MG, Pook DW, Wang H, Porter LH, Frydenberg M, Kourambas J, Appu S, Poole C, Beardsley EK, Ryan A, Norden S, Papargiris MM, Risbridger GP, Taylor RA.Prostate. 2015;75 (13): 1475-83.
• Predictors of prostate cancer-specific mortality after radical prostatectomy: 10-year oncologic outcomes from the Victorian Radical Prostatectomy Registry. Bolton DM, Papa N, Ta AD, Millar J, Davidson AJ, Pedersen J, Syme R, Patel MI, Giles GG. BJU Int. 2015;116 Suppl 3: 66-72.
• Does perineural invasion in a radical prostatectomy specimen predict biochemical recurrence in men with prostate cancer?. Reeves F, Hovens CM, Harewood L, Battye S, Peters JS, Costello AJ, Corcoran NM. Can Urol Assoc J. 2015;9 (5-6): E252-5.
• Comparison of [(11)C]choline Positron Emission Tomography With T2- and Diffusion-Weighted Magnetic Resonance Imaging for Delineating Malignant Intraprostatic Lesions. Chang JH, Lim Joon D, Davis ID, Lee ST, Hiew CY, Esler S, Gong SJ, Wada M, Clouston D, O’Sullivan R, Goh YP, Bolton D, Scott AM, Khoo V. Int. J. Radiat. Oncol. Biol. Phys. 2015;92 (2): 438-45.
• Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Hong MK, Macintyre G, Wedge DC, Van Loo P, Patel K, Lunke S, Alexandrov LB, Sloggett C, Cmero M, Marass F, Tsui D, Mangiola S, Lonie A, Naeem H, Sapre N, Phal PM, Kurganovs N, Chin X, Kerger M, Warren AY, Neal D, Gnanapragasam V, Rosenfeld N, Pedersen JS, Ryan A, Haviv I, Costello AJ, Corcoran NM, Hovens CM. Nat Commun. 2015;6: 6605.
• Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity. Takizawa I, Lawrence MG, Balanathan P, Rebello R, Pearson HB, Garg E, Pedersen J, Pouliot N, Nadon R,Watt MJ, Taylor RA, Humbert P, Topisirovic I, Larsson O, Risbridger GP, Furic L. Oncotarget. 2015;6 (2): 604-16.
• Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. Risbridger GP, Taylor RA, Clouston D, Sliwinski A, Thorne H, Hunter S, Li J, Mitchell G, Murphy D, Frydenberg M, Pook D, Pedersen J, Toivanen R, Wang H, Papargiris M, Lawrence MG, Bolton DM. Eur. Urol. 2015;67 (3): 496-503.
• Altered significance of D’Amico risk classification in patients with prostate cancer linked to a familial breast cancer (kConFab) cohort. Bolton D, Cheng Y, Willems-Jones AJ, Li J, Niedermeyr E, Mitchell G, Clouston D, Lawrentschuk N, Sliwinski A, Fox S, Thorne H. BJU Int. 2015;116 (2): 207-12.

2014

• A three-protein biomarker panel assessed in diagnostic tissue predicts death from prostate cancer for men with localized disease. Severi G, FitzGerald LM, Muller DC, Pedersen J, Longano A, Southey MC, Hopper JL, English DR, Giles GG, Mills J. Cancer Med. 2014;3 (5): 1266-74.
• Detection of infectious organisms in archival prostate cancer tissues. Yow MA, Tabrizi SN, Severi G, Bolton DM, Pedersen J, Longano A, Garland SM, Southey MC, Giles GG¹. BMC Cancer. 2014;14 (1): 579.
• A pro-tumourigenic loop at the human prostate tumour interface orchestrated by oestrogen, CXCL12 and mast cell recruitment. Ellem SJ, Taylor RA, Furic L, Larsson O, Frydenberg M, Pook D, Pedersen J, Cawsey B, Trotta A, Need E, Buchanan G,Risbridger GP.J. Pathol. 2014;234 (1): 86-98.
• Multiparametric 3T MRI in the evaluation of intraglandular prostate cancer: correlation with histopathology. Styles C, Ferris N, Mitchell C, Murphy D, Frydenberg M, Mills J, Pedersen J, Bergen N, Duchesne G. J Med Imaging Radiat Oncol. 2014;58 (4): 439-48.
• Comparison contemporary methods of estimating prostate tumor volume in pathological specimens. BJU Int. 2014 Mar; 113 Suppl 2:29-34.
• Diffusion-weighted MRI, (11)C-choline PET and (18)F-fluorodeoxyglucose PET for predicting the Gleason score in prostate carcinoma. Chang JH, Lim Joon D, Lee ST, Hiew CY, Esler S, Gong SJ, Wada M, Clouston D, O’Sullivan R, Goh YP, Tochon-Danguy H, Chan JG, Bolton D, Scott AM, Khoo V, Davis ID. Eur Radiol. Epub 2013 Nov 6
• Canonical androstenedione reduction is the predominant source of signaling androgens in hormone-refractory prostate cancer. Fankhauser M, Tan Y, Macintyre G, Haviv I, Hong MK, Nguyen A, Pedersen JS, Costello AJ, Hovens CM,Corcoran NM. Clin. Cancer Res. 2014;20 (21): 5547-57.
• Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists. Iczkowski KA, Egevad L, Ma J, Harding-Jackson N, Algaba F, Billis A, Camparo P, Cheng L, Clouston D, et al. Ann Diagn Pathol. 2014;18 (6): 333-42.
• Reducing the risk of false discovery enabling identification of biologically significant genome-wide methylation status using the HumanMethylation450 array. Naeem H, Wong NC, Chatterton Z, Hong MK, Pedersen JS, Corcoran NM, Hovens CM, Macintyre G. BMC Genomics. 2014;15 (1): 51.

2013

• Bladder cancer biorepositories in the “-omics” era: integrating quality tissue specimens with comprehensive clinical annotation. Sapre N, Hong MK, Huang JG, Pedersen J, Ryan A, Anderson P, Costello AJ, Corcoran NM, Hovens CM. Biopreserv Biobank. 2013;11 (3): 166-72.
• Hedgehog signaling is active in human prostate cancer stroma and regulates proliferation and differentiation of adjacent epithelium. Prostate. 2013;73 (16): 1810-23. Wilkinson SE, Furic L, Buchanan G, Larsson O, Pedersen J, Frydenberg M, Risbridger GP, Taylor RA.
• Metaplastic conditions of the bladder. BJU Int. 2013;112 Suppl 2: 27-31. Clouston D, Lawrentschuk N.
• Diffusion-weighted MRI, (11)C-choline PET and (18)F-fluorodeoxyglucose PET for predicting the Gleason score in prostate carcinoma. Eur Radiol 2013 Nov 6. [Epub ahead of print]. Chang JH, Lim Joon D, Lee ST, Hiew CY, Esler S, Gong SJ, Wada M, Clouston D, O’Sullivan R, Goh YP, Tochon-Danguy H, Chan JG, Bolton D, Scott AM, Khoo V, Davis ID.
• Extraprostatic Extension into Periprostatic Fat is a More Important Determinant of Prostate Cancer Recurrence than an Invasive Phenotype. J. Urol. 2013;190 (6): 2061-7. Kapoor J, Namdarian B, Pedersen J, Hovens C, Moon D, Peters J, Costello AJ, Ruljancich P, Corcoran NM.
• Comparison contemporary methods of estimating prostate tumor volume in pathological specimens. BJU Int. 2013; . Perera M, Lawrentschuk N, Bolton D, Closton D.
• Percutaneous image-guided biopsy of prostate cancer metastases yields samples suitable for genomics and personalised oncology. Clin. Exp. Metastasis – epub Oct 2. Hong MK, Sapre N, Phal PM, Macintyre G, Chin X, Pedersen JS, Ryan A, Kerger M, Costello AJ, Corcoran NM, Hovens CM.
• A preclinical xenograft model identifies castration-tolerant cancer-repopulating cells in localized prostate tumors. Sci Transl Med. 2013;5 (187): 187ra71. Toivanen R, Frydenberg M, Murphy D, Pedersen J, Ryan A, Pook D, Berman DM; Australian Prostate Cancer BioResource, Taylor RA, Risbridger GP.
• A preclinical xenograft model of prostate cancer using human tumors. Nat Protoc. 2013;8 (5): 836-48. Lawrence MG, Taylor RA, Toivanen R, Pedersen J, Norden S, Pook DW, Frydenberg M; Australian Prostate Cancer BioResource, Papargiris MM, Niranjan B,Richards MG, Wang H, Collins AT, Maitland NJ, Risbridger GP.
• Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer. BJU Int. 2013;111 (6): 921-7. Huang JG, Pedersen J, Hong MK, Harewood LM, Peters J, Costello AJ, Hovens CM, Corcoran NM.
• A bioengineered microenvironment to quantitatively measure the tumorigenic properties of cancer-associated fibroblasts in human prostate cancer. Biomaterials. 2013;34 (20): 4777-85. Clark AK, Taubenberger AV, Taylor RA, Niranjan B, Chea ZY, Zotenko E, Sieh S, Pedersen JS, Norden S, Frydenberg M, Grummet JP, Pook DW; Australian Prostate Cancer BioResource, Stirzaker C, Clark SJ, Lawrence MG, Ellem SJ, Hutmacher DW, Risbridger GP.
• Primary culture and propagation of human prostate epithelial cells. Methods Mol. Biol. 2013;945: 365-82. Niranjan B, Lawrence MG, Papargiris MM, Richards MG, Hussain S, Frydenberg M, Pedersen J, Taylor RA, Risbridger GP.
• Error rates in a clinical data repository: lessons from the transition to electronic data transfer – a descriptive study. Hong MK, Yao HH, Pedersen JS, Peters JS, Costello AJ, Murphy DG, Hovens CM, Corcoran NM. BMJ Open. 2013;3 (5)

2012

• Re-evaluating the biological significance of seminal vesicle invasion (SVI) in locally advanced prostate cancer. BJU Int. 2012;110 Suppl 4: 58-63. Sapre N, Pedersen J, Hong MK, Harewood L, Peters J, Costello AJ, Hovens CM, Corcoran NM.
• Utility of RhoC and ZAG protein expression as biomarkers for prediction of PSA failure following radical prostatectomy for high grade prostate cancer. Pathology. 2012;44 (6): 513-8. Mills J, Oliver A, Sherwin JC et-al. Mills J, Oliver A, Sherwin JC, Frydenberg M, Peters JS, Costello A, Harewood L, Love C, Redgrave N, van Golen KL, Bailey M, Pedersen J.
• Microscopic assessment of fresh prostate tumour specimens yields significantly increased rates of correctly annotated samples for downstream analysis. Pathology. 2012;44 (3): 204-8. Kerger M, Hong MK, Pedersen J, Nottle T, Ryan A, Mills J, Peters JS, Moon D, Crowe H, Costello AJ, Corcoran NM, Hovens CM.
  
• Prostate weight is the preferred measure of prostate size in radical prostatectomy cohorts. BJU Int. 2012;109 Suppl 3: 57-63. Hong MK, Yao HH, Rzetelski-West K, Namdarian B, Pedersen J, Peters JS, Hovens CM, Corcoran NM.
• Prostate tumour volume is an independent predictor of early biochemical recurrence in a high risk radical prostatectomy subgroup. Pathology. 2011;43 (2): 138-42. Hong MK, Namdarian B, Corcoran NM, Pedersen J, Murphy DG, Peters JS, Harewood L, Sapre N, Rzetelski-West K, Costello AJ, Hovens CM.
• Positive surgical margins are a risk factor for significant biochemical recurrence only in intermediate-risk disease. British Journal of Urology International – in press (2012). Corcoran NM, Hovens CM, Metcalfe C, Hong MK, Pedersen J, Casey RG, Peters J, Harewood L, Goldenberg SL, Costello AJ, Gleave ME.

2011

• The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. British Journal of Urology International (2011). Corcoran NM, Casey RG, Hong MK, Pedersen J, Connolly S, Peters J, Harewood L, Gleave ME, Costello AJ, Hovens CM, Goldenberg SL. http://www.ncbi.nlm.nih.gov/pubmed/22085203
• Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours. British Journal Urology International (2011). Corcoran NM, Hovens CM, Hong MK, Pedersen J, Casey RG, Connolly S, Peters J, Harewood L, Gleave ME, Goldenberg SL, Costello AJ – http://www.ncbi.nlm.nih.gov/pubmed/21895937
• Immunohistochemical study of the cavernous nerves in the periprostatic region. British Journal of Urology International (2011). Costello AJ, Dowdle BW, Namdarian B, Pedersen J, Murphy DG. http://www.ncbi.nlm.nih.gov/pubmed/20942832
• Prostate tumour volume is an independent predictor of early biochemical recurrence in a high risk radical prostatectomy subgroup.Pathology (2011). Hong MK, Namdarian B, Corcoran NM, Pedersen J, Murphy DG, Peters JS, Harewood L, Sapre N, Rzetelski-West K, Costello AJ, Hovens CM – http://www.ncbi.nlm.nih.gov/pubmed/21233675
• Loss of APKC expression independently predicts tumor recurrence in superficial bladder cancers. Urologic Oncology (2011). Namdarian B, Wong E, Galea R, Pedersen J, Chin X, Speirs R, Humbert PO, Costello AJ, Corcoran NM, Hovens CM – – http://www.ncbi.nlm.nih.gov/pubmed/21549621
• A new preoperative nomogram to predict minimal prostate cancer: accuracy and error rates compared to other tools to select patients for active surveillance. Journal of Urology (2011). O’Brien BA, Cohen RJ, Ryan A, Sengupta S, Mills J. http://www.ncbi.nlm.nih.gov/pubmed?term=ryan%20mills%20nomogram
• SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. Journal of Clinical Investigation (2011). Pearson HB, Perez-Mancera PA, Dow LE, Ryan A, Tennstedt P, Bogani D, Elsum I, Greenfield A, Tuveson DA, Simon R, Humbert PO – http://www.ncbi.nlm.nih.gov/pubmed/21965329
• Improved detection of mycobacteria species in formalin-fixed tissue sections. Histopathology (2011). Pedersen JS, Clarke I, Mills J. http://www.ncbi.nlm.nih.gov/pubmed/22092411
• Brief report: a bioassay to identify primary human prostate cancer repopulating cells. Stem Cells (2011). Toivanen R, Berman DM, Wang H, Pedersen J, Frydenberg M, Meeker AK, Ellem SJ, Risbridger GP, Taylor RA. – http://www.ncbi.nlm.nih.gov/pubmed/21674698

2010

• Snail expression is an independent predictor of tumor recurrence in superficial bladder cancers. Urologic Oncology (2010). Bruyere F, Namdarian B, Corcoran NM, Pedersen J, Ockrim J, Voelzke BB, Mete U, Costello AJ, Hovens CM – http://www.ncbi.nlm.nih.gov/pubmed/19162513
• Plasma concentration of Propionibacterium acnes antibodies and prostate cancer risk: results from an Australian population-based case-control study. British Journal of Cancer (2010). Severi G, Shannon BA, Hoang HN, Baglietto L, English DR, Hopper JL, Pedersen J, Southey MC, Sinclair R, Cohen RJ, Giles GG – http://www.ncbi.nlm.nih.gov/pubmed/20606679
• Tumor volume in radical prostatectomy specimens assessed by digital image analysis software correlates with other prognostic factors. Journal of Urology (2010). Sherwin JC, Mirmilstein G, Pedersen J, Lawrentschuk N, Bolton D, Mills J – http://www.ncbi.nlm.nih.gov/pubmed/20303103

2000-2009

• Elevated level of inhibin-alpha subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer. British Journal of Cancer (2009). Balanathan P, Williams ED, Wang H, Pedersen JS, Horvath LG, Achen MG, Stacker SA, Risbridger GP – http://www.ncbi.nlm.nih.gov/pubmed/19436293
• Aurora kinase B is an independent protective factor in superficial bladder tumours with a dysfunctional G1 checkpoint.
• British Journal of Urology International (2008). Bruyere F, Corcoran NM, Berdjis N, Namdarian B, Pedersen J, Ockrim J, Voelzke BB, Costello AJ, Hovens CM – http://www.ncbi.nlm.nih.gov/pubmed/18341621
• Early-onset endocrine disruptor-induced prostatitis in the rat. Environmental Health Perspectives (2008). Cowin PA, Foster P, Pedersen J, Hedwards S, McPherson SJ, Risbridger GP – http://www.ncbi.nlm.nih.gov/pubmed/21674698
• Molecular testing for paraffin embedded material. Pathology (2007). Gonzales M, Susman M, Dale S, Mills J – http://www.ncbi.nlm.nih.gov/pubmed/17886112
• Quantitation of chromosome 1p and 19q deletions in glial tumours by interphase FISH on formalin-fixed paraffin-embedded tissue. Journal of Clinical Neurosciences (2006). Gonzales M, Dale S, Susman M, Mills J. http://www.ncbi.nlm.nih.gov/pubmed/16410204
• Formation of human prostate tissue from embryonic stem cells. Nat Methods (2006). Taylor RA, Cowin PA, Cunha GR, Pera M, Trounson AO, Pedersen J, Risbridger GP – http://www.ncbi.nlm.nih.gov/pubmed/21674698
• Local aromatase expression in human prostate is altered in malignancy. J Clin Endocrinol Metab (2004). Ellem SJ, Schmitt JF, Pedersen JS, Frydenberg M, Risbridger GP – http://www.ncbi.nlm.nih.gov/pubmed/15126575
• Direct response of the murine prostate gland and seminal vesicles to estradiol. Endocrinology (2002). Bianco JJ, Handelsman DJ, Pedersen JS, Risbridger GP. http://www.ncbi.nlm.nih.gov/pubmed/12446620
• Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol Biomarkers Prev (2002). Jarred RA, Keikha M, Dowling C, McPherson SJ, Clare AM, Husband AJ, Pedersen JS, Frydenberg M, Risbridger GP. http://www.ncbi.nlm.nih.gov/pubmed/12496063
• Hypermethylation of the inhibin alpha-subunit gene in prostate carcinoma. Molecular Endocrinology (2002). Schmitt JF, Millar DS, Pedersen JS, Clark SL, Venter DJ, Frydenberg M, Molloy PL, Risbridger GP. http://www.ncbi.nlm.nih.gov/pubmed/11818495
• Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland. Endocrinology (2001). McPherson SJ, Wang H, Jones ME, Pedersen J, Iismaa TP, Wreford N, Simpson ER, Risbridger GP. http://www.ncbi.nlm.nih.gov/pubmed/11356695
• Localization of activin beta(A)-, beta(B)-, and beta(C)-subunits in humanprostate and evidence for formation of new activin heterodimers of beta(C)-subunit. J Clin Endocrinol Metab (2000). Mellor SL, Cranfield M, Ries R, Pedersen J, Cancilla B, de Kretser D, Groome NP, Mason AJ, Risbridger GP. http://www.ncbi.nlm.nih.gov/pubmed/11134153